![]() |
|
|
Complementary Medicine - Cam
Topic ContentsSt. John’s WortUsesCommon names: Hypericum, Klamath Weed
Botanical names: Hypericum perforatum
Parts Used & Where GrownSt. John’s wort is found in Europe and the United States. It is especially abundant in northern California and southern Oregon. The above-ground (aerial) parts of the plant are gathered during the flowering season.
What Are Star Ratings?
Our proprietary “Star-Rating” system was developed to help you easily understand the amount of scientific support behind each supplement in relation to a specific health condition. While there is no way to predict whether a vitamin, mineral, or herb will successfully treat or prevent associated health conditions, our unique ratings tell you how well these supplements are understood by the medical community, and whether studies have found them to be effective for other people. For over a decade, our team has combed through thousands of research articles published in reputable journals. To help you make educated decisions, and to better understand controversial or confusing supplements, our medical experts have digested the science into these three easy-to-follow ratings. We hope this provides you with a helpful resource to make informed decisions towards your health and well-being. 3 Stars Reliable and relatively consistent scientific data showing a substantial health benefit. 2 Stars Contradictory, insufficient, or preliminary studies suggesting a health benefit or minimal health benefit. 1 Star For an herb, supported by traditional use but minimal or no scientific evidence. For a supplement, little scientific support. This supplement has been used in connection with the following health conditions:
Traditional Use (May Not Be Supported by Scientific Studies)In ancient Greece, St. John’s wort was used to treat many ailments, including sciatica and poisonous reptile bites. In Europe, St. John’s wort was used by herbalists for the topical treatment of wounds and burns . It is also a folk remedy for kidney and lung ailments as well as for depression . How It WorksCommon names: Hypericum, Klamath Weed
Botanical names: Hypericum perforatum
How It WorksThe major constituents in St. John’s wort include hypericin and other dianthrones, flavonoids , xanthones, and hyperforin.39 While it was previously thought the antidepressant actions of St. John’s wort were due to hypericin and the inhibition of the enzyme monoamine oxidase,40 current research has challenged this belief, focusing on other constituents, such as hyperforin, and flavonoids.41 , 42 , 43 Test tube studies suggest that St. John’s wort extracts may exert their antidepressant actions by inhibiting the reuptake of the neurotransmitters serotonin, norepinephrine, and dopamine.44 This action is possibly due to the constituent hyperforin.45 St. John’s wort is able to act as an antidepressant, by making more of these neurotransmitters available to the brain. How to Use ItThe standard recommendation for mild to moderate depression is 500–1,050 mg of St. John’s wort extract per day.46 , 47 , 48 Results may be noted as early as two weeks. Length of use should be discussed with a healthcare professional. For more severe depression, higher intakes may be used, under the supervision of a healthcare professional. InteractionsCommon names: Hypericum, Klamath Weed
Botanical names: Hypericum perforatum
Interactions with Supplements, Foods, & Other CompoundsCaution: It is likely that there are many drug interactions with St. John's wort that have not yet been identified. St. John's wort stimulates a drug-metabolizing enzyme (cytochrome P450 3A4) that metabolizes at least 50% of the drugs on the market.49 Therefore, it could potentially cause a number of drug interactions that have not yet been reported. People taking any medication should consult with a doctor or pharmacist before taking St. John's wort. Interactions with MedicinesCertain medicines interact with this supplement.
Types of interactions:
Beneficial
Adverse
Check
Replenish Depleted Nutrients
Reduce Side Effects
Support Medicine
Reduces Effectiveness
Potential Negative Interaction
Explanation Required
The Drug-Nutrient Interactions table may not include every possible interaction. Taking medicines with meals, on an empty stomach, or with alcohol may influence their effects. For details, refer to the manufacturers’ package information as these are not covered in this table. If you take medications, always discuss the potential risks and benefits of adding a supplement with your doctor or pharmacist.
Side EffectsCommon names: Hypericum, Klamath Weed
Botanical names: Hypericum perforatum
Side EffectsSt. John’s wort has a low incidence of side effects compared to prescription antidepressants. An adverse events profile of St. John’s wort found that, of 14 controlled clinical trials, seven reported no adverse reactions, two had no information, and five reported a total of seven mild reactions.130 Adverse effects reported included stomach upset, fatigue, itching, sleep disturbance, and skin rash. The rate of adverse reactions was always similar to that of the placebo. Additionally, in seven trials comparing St. John’s wort with other antidepressants, the adverse reaction rate for St. John’s wort was consistently lower than that of the antidepressant drugs with which it was compared. St. John’s wort can make the skin more sensitive to sunlight.131 Therefore, fair-skinned people should be alert for any rashes or burns following exposure to the sun. Three cases of severe blistering and burns were reported in people taking St. John’s wort internally or applying it topically and then being exposed to sunlight.132 There is a case report of a woman experiencing neuropathy (nerve injury and pain) in sun-exposed skin areas after taking 500 mg of whole St. John’s wort for four weeks.133 Although St. John’s wort has photosensitizing properties, the severity of this reaction is not typical for people taking the herb. People with a history of manic-depressive illness ( bipolar disorder ) or a less severe condition known as hypomania, should avoid use of St. John’s wort as it may trigger a manic episode.134 , 135 , 136 , 137 There is a single case report in which ingestion of St. John's wort appeared to cause high blood pressure in a 56-year-old man. The blood pressure returned to normal when the herb was discontinued.138 Related Information
References1. Markowitz JS, Donovan JL, DeVane CL, et al. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003;290:1500–4. 2. Witte B, Harrer G, Kaptan T, et al. Treatment of depressive symptoms with a high concentration Hypericum preparation. A multicenter placebo-controlled double-blind study. Fortschr Med 1995;113:404–8 [in German]. 3. Markowitz JS, Donovan JL, DeVane CL, et al. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003;290:1500–4. 4. Harrer G, Sommer H. Treatment of mild/moderate depressions with Hypericum. Phytomedicine 1994;1:3–8. 5. Ernst E. St. John’s wort, an antidepressant? A systemic, criteria-based review. Phytomedicine 1995;2:67–71. 6. Kasper S, Anghelescu IG, Szegedi A, et al. Superior efficacy of St John's wort extract WS 5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN77277298]. BMC Med 2006 Jun 23;4:14. 7. Vorbach EU, Hübner WD, Arnoldt KH. Effectiveness and tolerance of the Hypericum extract LI 160 in comparison with imipramine: Randomized double-blind study with 135 outpatients. J Geriatr Psychiatry Neurol 1994;7(suppl):S19–23. 8. Philipp M, Kohnen R, Hiller KO. Hypericum extract versus imipramine or placebo in patients with moderate depression: randomized multicenter study of treatment for eight weeks. BMJ 1999;319:1534–9. 9. Woelk H. Comparison of St. John’s wort and imipramine for treating depression: Randomized controlled trial. BMJ 2000;321:536–9. 10. Wheatley D. LI 160, an extract of St. John’s wort versus amitriptyline in mildly to moderately depressed outpatients—controlled six week clinical trial. Pharmacopsychiatry 1997;30(suppl):77–80. 11. Volz HP, Laux P. Potential treatment for subthreshold and mild depression: a comparison of St. John’s wort extracts and fluoxetine. Compr Psychiatry 2000;41(2 Suppl 1):133–7 [review]. 12. Harrer G, Hübner WD, Poduzweit H. Effectiveness and tolerance of the Hypericum extract LI 160 compared to maprotiline: A multicenter double-blind study. J Geriatr Psychiatry Neurol 1994;7(suppl 1);S24–8. 13. Harrer G, Schmidt U, Kuhn U, Biller A. Comparison of equivalence between the St. John’s wort extract LoHyp-57 and fluoxetine. Arzneimittelforschung 1999;49:289–96. 14. Schrader D. Equivalence of St. John’s wort extract (ZE 117) and fluoxetine: a randomized, controlled study in mild – moderate depression. International Clin Psychopharmacol 2000;15:61–8. 15. Vorbach EU, Arnoldt KH, Hübner WD. Efficacy and tolerability of St. John’s wort extract LI 160 versus imipramine in patients with severe depressive episodes according to ICD-10. Pharmacopsychiatry 1997;30(suppl):81–5. 16. Shelton RC, Keller MB, Gelenberg A, et al. Effectiveness of St John's wort in major depression: a randomized controlled trial. JAMA 2001;285:1978–86. 17. Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St John's Wort) in major depressive disorder: a randomized controlled trial. JAMA 2002;287:1807–14. 18. Markowitz JS, Donovan JL, DeVane CL, et al. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003;290:1500–4. 19. Schempp CM, Windeck T, Hezel S, Simon JC. Topical treatment of atopic dermatitis with St. John’s wort cream—a randomized, placebo controlled, double blind half-side comparison. Phytomedicine 2003;10(Suppl 4):31–7. 20. Uebelhack R, Blohmer JU, Graubaum HJ, et al. Black cohosh and St. John's wort for climacteric complaints: a randomized trial. Obstet Gynecol 2006;107:247–55. 21. Markowitz JS, Donovan JL, DeVane CL, et al. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003;290:1500–4. 22. Kim HL, Streltzer J, Goebert D. St. John’s wort for depression: a meta-analysis of well-defined clinical trials. J Nerv Ment Dis 1999;187:532–8 [review]. 23. Martinez B, Kasper S, Ruhrmann S, Moller HJ. Hypericum in the treatment of seasonal affective disorders. J Geriatr Psychiatry Neurol 1994;7:S29–33. 24. Wheatley D. Hypericum in seasonal affective disorder (SAD). Curr Med Res Opin 1999;15:33–7. 25. Markowitz JS, Donovan JL, DeVane CL, et al. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003;290:1500–4. 26. Markowitz JS, Donovan JL, DeVane CL, et al. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003;290:1500–4. 27. Markowitz JS, Donovan JL, DeVane CL, et al. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003;290:1500–4. 28. Cooper WC, James J. An observational study of the safety and efficacy of hypericin in HIV+ subjects. Int Conf AIDS 1990;6:369 [abstract no. 2063]. 29. Steinbeck-Klose A, Wernet P. Successful long term treatment over 40 months of HIV-patients with intravenous hypericin. Int Conf AIDS 1993;9:470 [abstract no. PO-B26–2012]. 30. Gulick RM, McAuliffe V, Holden-Wiltse J, et al. Phase I studies of hypericin, the active compound in St. John’s wort, as an antiretroviral agent in HIV-infected adults. AIDS clinical trial group protocols 150 and 258. Ann Intern Med 1999;130:510–4. 31. Markowitz JS, Donovan JL, DeVane CL, et al. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003;290:1500–4. 32. Markowitz JS, Donovan JL, DeVane CL, et al. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003;290:1500–4. 33. Uebelhack R, Blohmer JU, Graubaum HJ, et al. Black cohosh and St. John's wort for climacteric complaints: a randomized trial. Obstet Gynecol 2006;107:247–55. 34. Grube B, Walper A, Wheatley D. St. John’s Wort extract: efficacy for menopausal symptoms of psychological origin. Adv Ther 1999;16:177–86. 35. Al-Akoum M, Maunsell E, Verreault R, et al. Effects of Hypericum perforatum (St. John's wort) on hot flashes and quality of life in perimenopausal women: a randomized pilot trial. Menopause 2009;16:307–14. 36. Markowitz JS, Donovan JL, DeVane CL, et al. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003;290:1500–4. 37. Weiss RF. Herbal Medicine. Beaconsfield, UK: Beaconsfield Publishers Ltd, 1989, 114–5. 38. Markowitz JS, Donovan JL, DeVane CL, et al. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003;290:1500–4. 39. Gruenwald J. Standardized St. John’s wort clinical monograph. Quart Rev Nat Med 1997;Winter:289–99. 40. Suzuki O, Katsumata Y, Oya M. Inhibition of monoamine oxidase by hypericin. Planta Med 1984;50:272–4. 41. Holzl J, Demisch L, Gollnik B. Investigations about antidepressive and mood changing effects of Hypericum perforatum. Planta Med 1989;55:643. 42. Chatterjee SS, Koch E, Noldner M, et al. Hyperforin with hypericum extract: Interactions with some neurotransmitter systems. Quart Rev Nat Med 1997;Summer:110. 43. Calapai G, Crupi A, Firenzuoli F, et al. Effects of Hypericum perforatum on levels of 5-hydroxytryptamine, noradrenaline and dopamine in the cortex, diencephalon and brainstem of the rat. J Pharm Pharmacol 1999;51:723–8. 44. Müller WE, Rolli M, Schäfer C, Hafner U. Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity. Pharmacopsychiatry 1997;30(suppl):102–7. 45. Müller WE, Singer A, Wonnemann M, et al. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract. Pharmacopsychiatry 1998;31(suppl):16–21. 46. Brown DJ. Herbal Prescriptions for Better Health. Rocklin, CA: Prima Publishing, 1996, 159–65. 47. Woelk H. Comparison of St. John’s wort and imipramine for treating depression: Randomized controlled trial. BMJ 2000;321:536–9. 48. Philipp M, Kohnen R, Hiller KO. Hypericum extract versus imipramine or placebo in patients with moderate depression: randomized multicenter study of treatment for eight weeks. BMJ 1999;319:1534–9. 49. Markowitz JS, Donovan JL, DeVane CL, et al. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003;290:1500–4. 50. Roby CA, Anderson GD, Kantor E, et al. St John's Wort: effect on CYP3A4 activity. Clin Pharmacol Ther 2000;67:451–7 51. Mai I, Schmider J, et al. Unpublished results, May, 1999. Reported in: Johne A, Brockmöller, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St. John’s wort (Hypericum perforatum). Clin Pharmacol Ther 1999;66:338–45. 52. Nebel A, Schneider BJ, Baker RK, Kroll DJ. Potential metabolic interaction between St. John’s wortand theophylline [letter]. Ann Pharmacother 1999;33:502. 53. Mai I, Schmider J, et al. Unpublished results, May, 1999. Reported in: Johne A, Brockmöller, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St. John’s wort (Hypericum perforatum). Clin Pharmacol Ther 1999;66:338–45. 54. Mai I, Schmider J, et al. Unpublished results, May, 1999. Reported in: Johne A, Brockmöller, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St. John’s wort (Hypericum perforatum). Clin Pharmacol Ther 1999;66:338–45. 55. Nebel A, Schneider BJ, Baker RK, Kroll DJ. Potential metabolic interaction between St. John’s wortand theophylline [letter]. Ann Pharmacother 1999;33:502. 56. Mai I, Schmider J, et al. Unpublished results, May, 1999. Reported in: Johne A, Brockmöller, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St. John’s wort (Hypericum perforatum). Clin Pharmacol Ther 1999;66:338–45. 57. Roby CA, Anderson GD, Kantor E, et al. St John's Wort: effect on CYP3A4 activity. Clin Pharmacol Ther 2000;67:451–7. 58. Mai I, Schmider J, et al. Unpublished results, May, 1999. Reported in: Johne A, Brockmöller, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St. John’s wort (Hypericum perforatum). Clin Pharmacol Ther 1999;66:338–45. 59. Nebel A, Schneider BJ, Baker RK, Kroll DJ. Potential metabolic interaction between St. John’s wortand theophylline [letter]. Ann Pharmacother 1999;33:502. 60. Mai I, Schmider J, et al. Unpublished results, May, 1999. Reported in: Johne A, Brockmöller, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St. John’s wort (Hypericum perforatum). Clin Pharmacol Ther 1999;66:338–45. 61. Mai I, Schmider J, et al. Unpublished results, May, 1999. Reported in: Johne A, Brockmöller, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St. John’s wort (Hypericum perforatum). Clin Pharmacol Ther 1999;66:338–45. 62. Rauschitzka F, Meir P, Turina M, et al. Acute transplant rejection due to Saint John’s wort. Lancet 2000;355:548–9 [letter]. 63. Ernst E. Second thoughts about safety of St. John’s wort. Lancet 1999;354:2014–6 [letter]. 64. Breidenbach T, Hoffmann MW, Becker T, et al. Drug interaction of St. John’s wort with ciclopsorin. Lancet 2000;355:1912 [letter]. 65. Mai I, Schmider J, et al. Unpublished results, May, 1999. Reported in: Johne A, Brockmöller, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St. John’s wort (Hypericum perforatum). Clin Pharmacol Ther 1999;66:338–45. 66. Nebel A, Schneider BJ, Baker RK, Kroll DJ. Potential metabolic interaction between St. John’s wortand theophylline [letter]. Ann Pharmacother 1999;33:502. 67. Mai I, Schmider J, et al. Unpublished results, May, 1999. Reported in: Johne A, Brockmöller, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St. John’s wort (Hypericum perforatum). Clin Pharmacol Ther 1999;66:338–45. 68. Safety of St. John’s wort (Hypericum perforatum)[letters to the editor from various authors]. Lancet 2000;355:575–7. 69. Ernst E. Second thoughts about safety of St. John’s wort [letter]. Lancet 1999;354:2014–6. 70. Johne A, Brockmöller, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St. John’s wort (Hypericum perforatum). Clin Pharmacol Ther 1999;66:338–45. 71. Nebel A, Schneider BJ, Baker RK, Kroll DJ. Potential metabolic interaction between St. John’s wortand theophylline [letter]. Ann Pharmacother 1999;33:502. 72. Mai I, Schmider J, et al. Unpublished results, May, 1999. Reported in: Johne A, Brockmöller, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St. John’s wort (Hypericum perforatum). Clin Pharmacol Ther 1999;66:338–45. 73. Mai I, Schmider J, et al. Unpublished results, May, 1999. Reported in: Johne A, Brockmöller, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St. John’s wort (Hypericum perforatum). Clin Pharmacol Ther 1999;66:338–45. 74. Nebel A, Schneider BJ, Baker RK, Kroll DJ. Potential metabolic interaction between St. John’s wortand theophylline [letter]. Ann Pharmacother 1999;33:502. 75. Mai I, Schmider J, et al. Unpublished results, May, 1999. Reported in: Johne A, Brockmöller, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St. John’s wort (Hypericum perforatum). Clin Pharmacol Ther 1999;66:338–45. 76. Safety of St. John’s wort (Hypericum perforatum)[letters to the editor from various authors]. Lancet 2000;355:575–7. 77. Ernst E. Second thoughts about safety of St. John’s wort [letter]. Lancet 1999;354:2014–6. 78. Safety of St. John’s wort (Hypericum perforatum)[letters to the editor from various authors]. Lancet 2000;355:575–7. 79. Ernst E. Second thoughts about safety of St. John’s wort [letter]. Lancet 1999;354:2014–6. 80. Safety of St. John’s wort (Hypericum perforatum)[letters to the editor from various authors]. Lancet 2000;355:575–7. 81. Ernst E. Second thoughts about safety of St. John’s wort [letter]. Lancet 1999;354:2014–6. 82. Safety of St. John’s wort (Hypericum perforatum)[letters to the editor from various authors]. Lancet 2000;355:575–7. 83. Ernst E. Second thoughts about safety of St. John’s wort [letter]. Lancet 1999;354:2014–6. 84. Demott K. St. John’s wort tied to serotonin syndrome. Clinical Psychiatry News 1998;26:28. 85. Gordon JB. SSRIs and St. John’s wort: possible toxicity? Am Fam Physician 1998;57:950. 86. Bekman SE, Sommi RW, Switzer J. Consumer sue of St. John’s wort: A survey on effectiveness, safety, and tolerability. Pharmacotherapy 2000;20:568–74. 87. Lantz MS, Buchalter E, Giambanco V. St. John’s wort and antidepressant drug interaction in the elderly. J Geriatr Psychiatry Neurol 1999;12:7–10. 88. Demott K. St. John’s wort tied to serotonin syndrome. Clin Psychiatr News 1998;26:28. 89. Gordon JB. SSRIs and St. John’s wort: possible toxicity? Am Fam Physician 1998;57:950. 90. Mai I, Schmider J, et al. Unpublished results, May, 1999. Reported in: Johne A, Brockmöller, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St. John’s wort (Hypericum perforatum). Clin Pharmacol Ther 1999;66:338–45. 91. Nebel A, Schneider BJ, Baker RK, Kroll DJ. Potential metabolic interaction between St. John’s wortand theophylline [letter]. Ann Pharmacother 1999;33:502. 92. Mai I, Schmider J, et al. Unpublished results, May, 1999. Reported in: Johne A, Brockmöller, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St. John’s wort (Hypericum perforatum). Clin Pharmacol Ther 1999;66:338–45. 93. Piscitelli SC, Burstein AH, Chaitt D, et al. Indinavir concentrations and St. John’s wort. Lancet 2000;355:547–8 [letter]. 94. Moore LB, Goodwin B, Jones SA, et al. St. John’s wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 2000;97:7500–2. 95. Piscitelli SC, Burstein AH, Chaitt D, et al. Indinavir concentrations and St. John’s wort. Lancet 2000;355:547–8 [letter]. 96. Safety of St. John’s wort (Hypericum perforatum)[letters to the editor from various authors]. Lancet 2000;355:575–7. 97. Ernst E. Second thoughts about safety of St. John’s wort [letter]. Lancet 1999;354:2014–6. 98. Safety of St. John’s wort (Hypericum perforatum)[letters to the editor from various authors]. Lancet 2000;355:575–7. 99. Ernst E. Second thoughts about safety of St. John’s wort [letter]. Lancet 1999;354:2014–6. 100. Roby CA, Anderson GD, Kantor E, et al. St John's Wort: effect on CYP3A4 activity. Clin Pharmacol Ther 2000;67:451–7. 101. Safety of St. John’s wort (Hypericum perforatum)[letters to the editor from various authors]. Lancet 2000;355:575–7. 102. Ernst E. Second thoughts about safety of St. John’s wort [letter]. Lancet 1999;354:2014–6. 103. Safety of St. John’s wort (Hypericum perforatum)[letters to the editor from various authors]. Lancet 2000;355:575–7. 104. Ernst E. Second thoughts about safety of St. John’s wort [letter]. Lancet 1999;354:2014–6. 105. Mai I, Schmider J, et al. Unpublished results, May, 1999. Reported in: Johne A, Brockmöller, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St. John’s wort (Hypericum perforatum). Clin Pharmacol Ther 1999;66:338–45. 106. Nebel A, Schneider BJ, Baker RK, Kroll DJ. Potential metabolic interaction between St. John’s wortand theophylline [letter]. Ann Pharmacother 1999;33:502. 107. Mai I, Schmider J, et al. Unpublished results, May, 1999. Reported in: Johne A, Brockmöller, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St. John’s wort (Hypericum perforatum). Clin Pharmacol Ther 1999;66:338–45. 108. Wang LS, Zhou G, Zhu B, et al. St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin Pharmacol Ther 2004;75:191–7. 109. Demott K. St. John’s wort tied to serotonin syndrome. Clinical Psychiatry News 1998;26:28. 110. Gordon JB. SSRIs and St. John’s Wort: possible toxicity? Am Fam Physician 1998;57:950. 111. St. John’s wort, Hypericum perforatum. In American Herbal Pharmacopoeia and Therapeutic Compendium, ed. R Upton. Santa Cruz, CA: AHP, 1997. 112. Mai I, Schmider J, et al. Unpublished results, May, 1999. Reported in: Johne A, Brockmöller, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St. John’s wort (Hypericum perforatum). Clin Pharmacol Ther 1999;66:338–45. 113. Nebel A, Schneider BJ, Baker RK, Kroll DJ. Potential metabolic interaction between St. John’s wortand theophylline [letter]. Ann Pharmacother 1999;33:502. 114. Mai I, Schmider J, et al. Unpublished results, May, 1999. Reported in: Johne A, Brockmöller, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St. John’s wort (Hypericum perforatum). Clin Pharmacol Ther 1999;66:338–45. 115. Demott K. St. John’s wort tied to serotonin syndrome. Clinical Psychiatry News 1998;26:28. 116. Gordon JB. SSRIs and St. John’s wort: possible toxicity? Am Fam Physician 1998;57:950. 117. Eggertsen R, Andreasson A, Andren L. Effects of treatment with a commercially available St John's Wort product (Movina) on cholesterol levels in patients with hypercholesterolemia treated with simvastatin. Scand J Prim Health Care 207;25:154–9. 118. Nebel A, Schneider BJ, Baker RK, Kroll DJ. Potential metabolic interaction between St. John’s wort and theophylline [letter]. Ann Pharmacother 1999;33:502. 119. Nebel A, Schneider BJ, Baker RK, Kroll DJ. Potential metabolic interaction between St. John’s wort and theophylline [letter]. Ann Pharmacother 1999;33:502. 120. Mai I, Schmider J, et al. Unpublished results, May, 1999. Reported in: Johne A, Brockmöller, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St. John’s wort (Hypericum perforatum). Clin Pharmacol Ther 1999;66:338–45. 121. Demott K. St. John’s wort tied to serotonin syndrome. Clinical Psychiatry News 1998;26:28. 122. Mai I, Schmider J, et al. Unpublished results, May, 1999. Reported in: Johne A, Brockmöller, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St. John’s wort (Hypericum perforatum). Clin Pharmacol Ther 1999;66:338–45. 123. Nebel A, Schneider BJ, Baker RK, Kroll DJ. Potential metabolic interaction between St. John’s wortand theophylline [letter]. Ann Pharmacother 1999;33:502. 124. Mai I, Schmider J, et al. Unpublished results, May, 1999. Reported in: Johne A, Brockmöller, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St. John’s wort (Hypericum perforatum). Clin Pharmacol Ther 1999;66:338–45. 125. Mauer A, Johne A, Bauer S, et al. Interaction of St. John’s wort extract with phenprocoumon [abstract]. Eur J Clin Pharmacol 1999;55:A22. 126. Safety of St. John’s wort (Hypericum perforatum)[letters, various authors]. Lancet 2000;355:575–7. 127. Nebel A, Schneider BJ, Baker RK, Kroll DJ. Potential metabolic interaction between St. John’s wort and theophylline [letter]. Ann Pharmacother 1999;33:502. 128. Mai I, Schmider J, et al. Unpublished results, May 1999. Reported in: Johne A, Brockmöller J, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St. John’s wort (Hypericum perforatum). Clin Pharmacol Ther 1999;66:338–45. 129. Wang Z, Hamman MA, Huang SM, et al. Effect of St John's wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther2002;71:414–20. 130. Ernst E, Rand JI, Barnes J, et al. Adverse effects profile of the herbal antidepressant St. John’s wort (Hypericum perforatum L.) Eur J Clin Pharmacol 1998;54:589–94. 131. Brockmöller J, Reum T, Bauer S, et al. Hypericin and pseudohypericin: Pharmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry 1997;30(suppl):94–101. 132. Lane-Brown MM. Photosensitivity associated with herbal preparations of St. John’s wort (Hypericum perforatum). MJA 2000;172:302[Letter]. 133. Bove GM. Acute neuropathy after exposure to sun in a patient treated with St John’s Wort. Lancet 1998;352:1121–2 [letter]. 134. Nierenberg AA, Burt T, Matthews J, Weiss AP. Mania associated with St. John’s wort. Biol Psychiatry 1999;46:1707–8. 135. Moses EL, Mallinger AG. St. John’s wort: Three cases of possible mania induction. J Clin Psychopharmacol 2000;20:115–7. 136. O’Breasail AM, Argouarch S. Hypomania and St John’s wort. Can J Psychiatry 1998;43:746–7 [letter]. 137. Schneck C. St. John’s wort and hypomania. J Clin Psychiatry 1998;59:689 [letter]. 138. Zullino D, Borgeat F. Hypertension induced by St. John's Wort: a case report. Pharmacopsychiatry. 2003;36:32.
Last Review: 11-07-2012 Copyright © 2012 Aisle7. All rights reserved. Aisle7.com Learn more about Aisle7, the company. The information presented in Aisle7 is for informational purposes only. It is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over the counter medication is also available. Consult your doctor, practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications. Information expires June 2013. This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated. |
||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||



